Approval · Notice of Compliance 21151 · 2018
AURO-ELETRIPTAN: Notice of Compliance 21151
Issued July 26, 2018
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 21151
- Date
- July 26, 2018
- Company
- Auro Pharma Inc.Woodbridge, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Abbreviated New Drug Submission (ANDS)
- Submission class
- Other
- Canadian reference product
- RELPAX (Pfizer Canada Ulc)
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| AURO-ELETRIPTAN | 02479451 | Marketed |
| AURO-ELETRIPTAN | 02479478 | Marketed |
Medicinal ingredients
- ELETRIPTAN HYDROBROMIDE 20 MG per TAB
- ELETRIPTAN HYDROBROMIDE 40 MG per TAB